Fenclozic acid (I.C.I. 54,450; 2-(p-chlorophenyl) thiazol-4-ylacetic acid; Myalex*) (Hepworth, Newbould, Platt, and Stacey, 1969) is one representative of a series of thiazolyl acetic acids which was active in the adjuvant-induced arthritis test in rats (Newbould, 1963) and which merited more detailed evaluation on this and other laboratory models (Newbould, 1969) .
Fenclozic acid (I.C.I. 54,450; 2-(p-chlorophenyl) thiazol-4-ylacetic acid; Myalex*) (Hepworth, Newbould, Platt, and Stacey, 1969) is one representative of a series of thiazolyl acetic acids which was active in the adjuvant-induced arthritis test in rats (Newbould, 1963) and which merited more detailed evaluation on this and other laboratory models (Newbould, 1969) .
Serum concentration studies in laboratory animals (Platt, 1969) showed that, at therapeutically active doses, fenclozic acid was distributed within the "albumin space" (c. 10-15 per cent. body weight) in rats, mice, guinea-pigs, dogs, and monkeys. Furthermore, a standard dose, measured in mg./kg. by mouth in each of these species gave similar peak serum concentrations. The half-life of elimination from animal serum varied between 3 hours in monkeys and 30 to 40 hours in rats. The relationship between the activity of fenclozic acid and serum levels in the rat showed that significant anti-inflammatory activity was associated with serum levels in the range 50-100 ,ug./ml. (Platt, 1969) . These data therefore enabled a serum level range to be defined for preliminary clinical trials in man.
The first studies in man were made in healthy individuals to enable the serum concentrations in man to be related to those found in animals. Subsequently, the compound was tested in patients with rheumatoid arthritis to whom the nature of the experiment had been explained and whose cooperation had been invited. The latter studies comprised a short trial to compare the serum concentrations of the drug in patients with those in healthy individuals, followed by a double-blind trial in patients with rheumatoid arthritis in which *Myalex is a trade mark, the property of Imperial Chemical Industries Ltd. the activity of fenclozic acid was compared with that of aspirin. To facilitate studies in patients, fenclozic acid was administered in capsule form. To ensure that comparable absorption could be obtained from tablet and capsule formulations, three of the normal subjects took single doses (200 mg.) of each form. The serum levels were compared in each subject for each formulation, no significant difference being detectable.
Five patients with rheumatoid arthritis were given repeated doses of fenclozic acid to enable a comparison to be made with the results from the normal individuals. One patient received three doses of 50 mg. at 12 hourly intervals followed by twelve doses of 100 mg. twice daily, while the remaining four patients took fifteen doses of 150 mg. twice daily. Serum samples were taken during and after treatment for drug assay.
In both groups studied, all other medication was withdrawn, with the exception of chloroquine and paracetamol, neither of which interfere with the assay of fenclozic acid.
The concentration of fenclozic acid in serum was assayed by the method reported elsewhere (Platt, 1969) . In addition to the drug concentration determinations, assays were also made on all the samples obtained for the activities of serum glutamic-oxalacetic transaminase (SGOT), isocitrate dehydrogenase (ICDH), and alkaline phosphatase, and for the concentrations of total protein and albumin. Routine haematology was performed on the patient samples.
Analysis of the accumulation of fenclozic acid in serum after repeated administration was made using the mathematical techniques given by Hammer and Brodie (1967) , van Rossum and Tomey (1968) , and Platt (1969) .
Results
Maximum serum concentrations in healthy individuals were observed at 3 hrs (or less) after an oral dose (Table I) and there was a linear relationship between this dose and the peak serum concentration in the dose range examined, c. 1 to 7 mg./kg.
( Figure) . An average peak level of 9 * 3 jig./ml.
was associated with a single dose of 1 mg./kg. body weight. The average serum half-life was 25 hrs (range 18 to 31). An accurate estimate of the volume of distribution (Vd) is not possible from the results given in Table I , but an approximation of the apparent Vd is shown in Table I , indicating that fenclozic acid is distributed at most into a volume corresponding to the albumin-space of the body. In the range of doses examined, the dose level had no effect on either the serum half-life or the apparent Vd of the drug. The properties of fenclozic acid in man were essentially similar to those observed in rats, guineapigs, and dogs (Table II) , man giving the highest serum levels dose for dose. Equilibrium dialysis experiments have shown that fenclozic acid is extensively bound to serum proteins, particularly albumin, in both animal and human serum. 1*47+0*09 13-6±0-9 11*2±0-4 54±0: ..l Repeated administration of the compound showed that fenclozic acid accumulated in human serum (Table III) Accumulation of fenclozic acid in serum after repeated administration was again apparent in patients with rheumatoid arthritis (Table IV, tPeak levels 2 to 3 hrs after dose.
tPlateau maximum concentration calculated (Methods Section) from the observed serum half-life, the average maximum concentration after one dose, and a fixed dosing interval of 12 hrs. tLevels recorded 2 to 3 hrs after dose. tHalf-life determined from samples taken up to 98 hrs after 15th dose. man and that the compound is distributed within the albumin-space of the body (c. 10 to 15 per cent. body weight) and has a long half-life. After repeated administration, accumulation of the compound occurs in human serum, the rate and extent of which are predictable.
It is of interest that the compound has a greater average half-life in arthritic patients than in healthy individuals, despite a lower dose-serum level response after single doses. The five arthritic patients had low serum albumin levels in agreement with previous observations (e.g. Reynolds and Cluff, 1960; Bernstein and Allerhand, 1964) . It is possible that the reduced serum levels of fenclozic acid in these patients after single doses were related to the low albumin levels, since Bayles (1963) has observed a similar phenomenon for salicylate levels in arthritic patients. The binding characteristics of fenclozic acid to serum albumin could also be affected in the disease state, possibly leading to an altered rate of elimination from serum, i.e. half-life but this has yet to be confirmed.
The results of these studies in normal subjects and patients suggested that doses of 100-200 mg. twice daily would give serum levels of fenclozic acid in man comparable with those required for significant anti-inflammatory activity in laboratory animals, i.e. 50 to 100 ,ug./ml. The double-blind cross-over trial against aspirin reported in our second paper was carried out, therefore, on the basis of this information.
Summarv
Fenclozic acid has been administered orally to normal subjects and also to patients with rheumatoid arthritis. Se ha suministrado, por via oral, acido fencl6sico a sujetos normales y tambien a pacientes con poliartritis reumatoide. Se midieron las concentraciones s6ricas de la droga y se relacionaron con resultados obtenidos en animales de laboratorio. Se descubri6 que el Acido fencl6sico tenia un periodo largo en el suero en el hombre y que se distribuia en la albfimina del cuerpo. Los pacientes con poliartritis reumatoide mostraron una reacci6n mas debil que los individuos sanos, pero revelaron un periodo serico ma's largo deladroga. Repetidos experimentos permitieron determinar la tasa y el grado de acumulaci6n de Acido fencl6sico en el suero humano. Las dosis adecuadas para la evaluaci6n preliminar de la actividad antiinflamatoria del acido fencl6sico en una prueba cruzada dobleciego con aspirina se determinaron a base de los resultados presentados.
